Clinical Trials
10 trialsNCT03258593 2026-03-17
Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT06263582 2025-08-19
Pharmacokinetics of Intravaginal, Self-administered Artesunate Vaginal Pessaries Among Women in Kenya
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT03808818 2025-03-18
Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices
Eastern Cooperative Oncology Group
Phase NA Completed
NCT01625260 2024-07-19
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
Phase 1/2 Terminated
NCT02901548 2022-07-29
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00402779 2020-04-21
Erlotinib Prevention of Oral Cancer (EPOC)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01200992 2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3 Terminated
NCT01192204 2015-08-14
Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Ohio State University
Phase 1/2 Completed